The treatment of osteoarthritis with new injectable cells may be successful.

Published Date: 26 Apr 2023

Researchers from the Wake Forest Institute for Regenerative Medicine (WFIRM) have developed a promising injectable cell therapy for osteoarthritis that not only lowers inflammation but also regenerates articular cartilage.

Read Full News

Latest News

PT Beats CBT for First-Line Low Back Pain Treatment

Findings of a real-world study confirm guidelines that recommend physical therapy as first-line treatment; it has a slight edge over cognitive-behavioral therapy.

Do Palindromic Flares Indicate Future Arthritis Joint Sites?

Palindromic rheumatism often begins with hand and shoulder involvement, and patients who progress to persistent inflammatory arthritis develop it in joints affected by prior palindromic flares.

Prescribing Walks Wisely in Low Back Pain

Individualized walking programs can reduce recurrent, disabling low back pain, but clinicians should screen for lower extremity biomechanical vulnerabilities and favor low impact options when needed.

Winter Sports and Lower Limb Motor Disability

People with lower limb motor disability need tailored equipment, training, and medical oversight to boost performance while preventing upper limb overload and skin problems.

Early Sports Specialization Affects Hip Development

New research suggests that kids who focus on one sport are more likely to experience physical problems later, hip injury in particular.

Ascendis Wins US Approval for Therapy for Children With Dwarfism

The U.S. Food and Drug Administration on Friday approved Ascendis Pharma's once-weekly therapy ⁠for children with a rare genetic disorder that causes dwarfism, the company...

Todays Updates

CAR-T Induces Deep, Durable Remission in Smoldering Myeloma

In a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained MRD-negative for more than 15 months. But is it a cure?

‘Bar Code’ Biopsy From RNA Could Guide Precision Oncology

New research shows how certain orphan noncoding RNA — oncRNA — can be predictable enough to be a ‘bar code’ identifying specific cancers. Liquid biopsy could be next.

Dasatinib Fails to Improve Outcomes in CBF-AML

A phase 3 study investigates the outcomes associated with intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

CD39 Blockade Shows Potential in Early-Stage Lung Cancer

A single-arm study hints at an uptick in pathologic complete responses when a CD39 blocker is added to perioperative durvalumab and chemotherapy for NSCLC.

Measurable Residual Disease Predicts Real-World AML Relapse

A study of a real-world population underscores measurable residual disease thresholds indicative of the risk for relapse in NPM1-mutated AML, suggesting guidance in treatment decisions.

Todays Updates

CAR-T Induces Deep, Durable Remission in Smoldering Myeloma

In a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained MRD-negative for more than 15 months. But is it a cure?

‘Bar Code’ Biopsy From RNA Could Guide Precision Oncology

New research shows how certain orphan noncoding RNA — oncRNA — can be predictable enough to be a ‘bar code’ identifying specific cancers. Liquid biopsy could be next.

Dasatinib Fails to Improve Outcomes in CBF-AML

A phase 3 study investigates the outcomes associated with intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

CD39 Blockade Shows Potential in Early-Stage Lung Cancer

A single-arm study hints at an uptick in pathologic complete responses when a CD39 blocker is added to perioperative durvalumab and chemotherapy for NSCLC.

Measurable Residual Disease Predicts Real-World AML Relapse

A study of a real-world population underscores measurable residual disease thresholds indicative of the risk for relapse in NPM1-mutated AML, suggesting guidance in treatment decisions.

Latest News

Findings of a real-world study confirm guidelines that recommend physical therapy as first-line treatment; it has a slight edge over cognitive-behavioral therapy.

Palindromic rheumatism often begins with hand and shoulder involvement, and patients who progress to persistent inflammatory arthritis develop it in joints affected by prior palindromic flares.

Individualized walking programs can reduce recurrent, disabling low back pain, but clinicians should screen for lower extremity biomechanical vulnerabilities and favor low impact options when needed.

People with lower limb motor disability need tailored equipment, training, and medical oversight to boost performance while preventing upper limb overload and skin problems.

New research suggests that kids who focus on one sport are more likely to experience physical problems later, hip injury in particular.

The U.S. Food and Drug Administration on Friday approved Ascendis Pharma's once-weekly therapy ⁠for children with a rare genetic disorder that causes dwarfism, the company...

News All Time

Arthritis pain rising: How state policies matter

New research from The University of Texas at Arlington shows that differences in state welfare policies are linked to rising arthritis-related joint pain across much of the U.S.

Customizable finger brace toggles between stiff and flexible for easier recovery

A friend's struggles with arthritis and the finger braces used to manage it inspired research by a Carnegie Mellon University student that could make it easier for patients to follow rehabilitation plans, speed up recovery ...

AI predicts future X-rays to help osteoarthritis patients and their doctors see what's coming

An AI system that can predict what a patient's knee X-ray will look like a year in the future could transform how millions of people with osteoarthritis understand and manage their condition, according to research by the ...

Joint pain or osteoarthritis? Exercise could be the first line of treatment

Stiff knees, aching hips and the slow grind of chronic joint pain are often accepted as an unavoidable part of getting older. But while osteoarthritis is the world's most common joint disease, experts say the way we treat ...

Study finds tailored exercise program feasible for adults over 80 with osteoarthritis

A new NDORMS study has found that a tailored exercise program for people aged 80 years and older with hip and/or knee osteoarthritis and other long term health conditions is both practical and acceptable, paving the way for ...

New treatment for psoriatic arthritis shows promising results in early trial

A new treatment for a debilitating inflammatory condition which affects joints and skin has shown promising early results in an international clinical trial of more than 200 patients worldwide.

Seven-year study reveals rheumatoid arthritis begins long before symptoms, opening door to prevention 

Scientists have discovered that rheumatoid arthritis (RA) doesn't start when the pain begins. It silently starts years earlier. RA is a debilitating autoimmune disease that causes painful joint inflammation and damage. The ...

Analysis isolates population aging as primary driver of musculoskeletal disorders

Novel research shows that in approximately one third of countries and territories worldwide, population aging was the largest contributor to the growing burden of musculoskeletal disorders from 1990 to 2021.

Self-guided online program improves quality of life in rheumatoid arthritis, psoriatic arthritis and lupus

Patients with rheumatoid arthritis, psoriatic arthritis, and systemic lupus erythematosus frequently face anxiety and depression along with chronic physical symptoms. Reported rates of depression range from 15% to 24% and ...

Tirzepatide found to be more cost-effective than semaglutide in patients with knee osteoarthritis, obesity

A microsimulation model was used to evaluate the cost-effectiveness of two glucagon-like peptide-1 receptor agonists (GLP1RAs), semaglutide and tirzepatide, for patients with osteoarthritis and obesity compared with usual ...

Current research may open doors to new treatments for children with juvenile dermatomyositis

Children with a rare, debilitating muscle disease could benefit from the findings of new research by experts at UCL and Great Ormond Street Hospital (GOSH).

Squishy 'smart cartilage' could target arthritis pain as soon as flareups begin

Researchers have developed a material that can sense tiny changes within the body, such as during an arthritis flareup, and release drugs exactly where and when they are needed.

Immune aging may be a driver of rheumatoid arthritis rather than a consequence

Features of immune system aging can be detected in the earliest stages of rheumatoid arthritis (RA), even before clinical diagnosis, a new study has found which provides at-risk individuals with hope for early intervention.

Common arthritis drug found to lower blood pressure and risk of heart disease

Methotrexate, a common medication used to treat rheumatoid arthritis, has a newly recognized useful secondary effect of lowering blood pressure and potentially reduces the risk of heart disease in people with this condition.

Noisy knees not an early arthritis sign, says new study

Knee crepitus, the sound of cracking or grinding in the knee joint, is very common across all age groups.

Q&A: These genetic insights into rheumatoid arthritis could help design better treatments

People with rheumatoid arthritis (RA) often have trouble getting out of bed in the morning, let alone getting to the rheumatologist for a checkup or participating in a research study. This makes a deeper understanding of ...

Recommended News For You

Metastatic breast cancer can be effectively treated with cyclical estrogen and anti-estrogen therapy.

Waist circumference outshines BMI as obesity-related cancer risk marker in men, but not women

High numbers of rural patients cross state lines for cancer care

10-year study shows tomosynthesis improves breast cancer detection

Year in Review: Non-Small Cell Lung Cancer

Early Esophageal Cancer pCR Rates Are Raised by Neoadjuvant PD-1 Blockade.

New research points out a promising strategy for treating metastatic medulloblastoma

Recommended Articles For You

Emerging Therapies and Technologies Reshaping Oncology: Innovations and Impact in 2025 

Cardiotoxicity Beyond Anthracyclines: Redefining Risk in the Cardio-Oncology Era 

Inside Oncology Trials: From Protocol to Progress in Cancer Research and Care 

Hematologic Cytomorphology: From Microscopy to Molecular Diagnostics 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

What is a "cancer vaccine" and is it the same as a COVID vaccine?

2.

The Higher the Disability Burden From Disease, the Higher the Suicide Risk

3.

Next Day Mood Is Affected by Ability to Recover From Work.

4.

MRI-Guided TULSA Speeds Recovery vs Robotic Prostatectomy

5.

Cancer mortality continuing to decline, says report

1.

The Growing Crisis of Aplastic Anemia: A Call for Action

2.

Evolving Cancer Treatments: Innovations, Success Rates, and Mechanisms

3.

Emerging Therapies and Technologies Reshaping Oncology: Innovations and Impact in 2025

4.

Esophageal Cancer Survival Rates and Outcomes: Evidence-Based Insights from Oncology Studies

5.

Integrating Immunotherapy and Staging Guidelines in Lung Cancer Treatment

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

CNS Clarity from Day One: Rethinking Early Diagnostic Strategies in ALK+NSCLC

2.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII

3.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III

4.

Navigating the Complexities of Ph Negative ALL - Part II

5.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot